ImmunityBio, Inc.
IBRX
NASDAQ·Healthcare·Biotechnology·Mkt cap $8.4B
$8.05
▼ -4.17%
P/E
-8.27
Mkt Cap
$8.4B
52-Wk Range
$1.95–$12.43
52-Week Range
$1.95 - $12.43
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 238.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Multi-platform technology approach reducing single-asset risk
- Strategic partnerships with NCI and leading biotech collaborators
- Diverse clinical pipeline spanning solid and liquid tumors
- Proprietary natural killer and T cell engineering capabilities
Bear Case
1 risk
- Low volatility (beta 0.1).
Growth
Strong growth ahead
Phase II/III clinical trial progression for multiple cancer indications
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Strong
+7.0% over 3m
Quality
Excellent
Emerging growth company (193% revenue growth). Early stage with higher risk.
Dividend
None
No dividend
Smart-money signal
Who's buying IBRX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 4, 2026
Reported EPS of -$0.22 vs -$0.08 consensus (-175.0% surprise). Revenue of $51.2M vs $49.7M expected (+3.1%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-175.0%
Revenue trend · last 8Q
—
—
—
—
+425%
+407%
+168%
+94%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$6.1M
$7.6M
$16.5M
$26.4M
$32.1M
$38.3M
$44.2M
$51.2M
Margins · last 8Q
Gross
99.4%
Operating
-120.4%
Profit
-449.6%
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: BTIG · May 21, 2026
vs Industry
How IBRX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related